R&D

#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes Endpoints NewsWhy Lilly and Novo…

#EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy Endpoints NewsThe Next Frontier for Obesity Drugs Isn’t…

Roche has scrapped development of a muscle-building drug, ending a trial testing the experimental medicine in combination with…

Yatsen Group, the Chinese beauty company behind Perfect Diary cosmetics, plans to deepen its push into skincare and…

Singapore designs bioinspired nanoparticles that deliver gene editing to lower bad cholesterol August 26, 2026 | Wednesday |…

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove…

Science Corporate, university expenditures for 2024 include computers, electronics China’s jump in R&D spending was driven by corporate…

A top theoretical journal of the Communist Party has acknowledged that a stark economic divide exists between China’s…

The Israel Innovation Authority plans to invest NIS 100 million ($33 million) to establish national infrastructure for research…

Retraction of high-profile paper on cancer drug timing could hand ammo to China hawks Endpoints NewsNature retracts provocative PD-1…

AMD believes customer collaboration and an open ecosystem are fundamental to accelerating AI innovation. By co-developing solutions with…

Phase 3 trials show oral semaglutide failed to slow early Alzheimer’s progression, potentially limiting its expansion beyond metabolic…

#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes – Endpoints News